Category: Press Releases

Press Releases

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

Sep 8, 2026

VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

Aug 19, 2026

VANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt treibt das GLP-1-Programm für sublinguales Semaglutid (ODF) voran – nächste Phase der Verabreichungsentwicklung läuft

Jul 6, 2026

VANCOUVER, BC / ACCESS Newswire / 6. Juli 2026 / BioNxt Solutions Inc. („BioNxt“ oder das „Unternehmen“) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives Biowissenschaftsunternehmen, das sich auf fortschrittliche Arzneimittelverabreichungssysteme spezialisiert hat,...

Continue Reading

Press Releases

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Jun 15, 2026

VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

May 19, 2026

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

Apr 28, 2026

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

Apr 14, 2026

VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

Apr 7, 2026

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

Mar 30, 2026

VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

Mar 24, 2026

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Mar 17, 2026

VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

Feb 17, 2026

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug...

Continue Reading